App-Quantinova.ai

GUSELKUMAB PROVIDES CONTINUED IMPROVEMENT IN KEY DOMAINS OF PSORIATIC ARTHRITIS THROUGH 2 YEARS

L. Coates - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

guselkumab (IV)

Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

J. Curtis - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

guselkumab (IV)

Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

J. Curtis - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Guselkumab improves dactylitis in PsA patients with inadequate response to TNFi: data from the Phase 3b COSMOS trial

H. Marzo-Ortega - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Dactylitis

guselkumab (IV)

HARD TIMES: ADAPTING A FATIGUE MANAGEMENT PROGRAMME IN A PANDEMIC

J. Dobson - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hand Osteoarthritis: investigating Pain Effects in a randomised placebo-controlled feasibility study of estrogen-containing therapy (HOPE-e): report on the primary feasibility outcomes

J. A. E. Williams - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Osteoarthritis 2

Conjugated estrogens/bazedoxifene

HEALTH PROFESSIONALS’ PERSPECTIVES ON THE USE OF JANUS KINASE INHIBITORS TO TREAT PATIENTS WITH INFLAMMATORY ARTHRITIS

S. De Souza - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY.

S. Grignaschi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

HIGH SENSITIVITY TROPONIN I IS ASSOCIATED WITH FOCAL FIBROSIS AS DETECTED BY CARDIAC MR IN EARLY, TREATMENT-NAIVE RA

R. Shukla - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arterial stiffness

N/A

HIGHLY DIFFERENTIATED CD4 AND CD8 T EFFECTOR MEMORY CELLS RE-EXPRESSING CD45RA (TEMRA) ARE ASSOCIATED WITH ACTIVE DISEASE REFRACTORY TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS

S. A. Yeoh - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

HLA-DRB1 ASSOCIATIONS WITH AUTOANTIBODY-DEFINED SUBGROUPS IN IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM)

V. Leclair - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMDs THROUGHOUT THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2)

M. Garrido-Cumbrera - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Depression

N/A

HOW GOOD ARE WE AT CAPTURING THE GI SYMPTOMS IN OUR PATIENTS WITH SCLERODERMA?

R. Parry - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Constipation

Anorectal Cream

HOW IS EARLY SPONDYLOARTHRITIS DEFINED IN THE LITERATURE? RESULTS FROM A SYSTEMATIC REVIEW

D. Benavent - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

HYDROXYCHLOROQUINE REDUCES THE TITERS OF ANTI-DOMAIN 1 ANTIBODIES OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES: RESULTS FROM THE APS ACTION CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)

C. Chighizola - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

IDENTIFICATION OF CAUSAL GENES AND MECHANISMS BY WHICH GENETIC VARIATION MEDIATES JUVENILE IDIOPATHIC ARTHRITIS SUSCEPTIBILITY USING FUNCTIONAL GENOMICS AND CRISPR-CAS9

A. Frantzesko - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

IDENTIFICATION OF NEW CANDIDATE DRUGS FOR PRIMARY SJÖGREN’S SYNDROME USING A DRUG REPURPOSING TRANSCRIPTOMIC APPROACH

R. Felten - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

IDENTIFICATION OF PsA PHENOTYPES WITH MACHINE LEARNING ANALYTICS USING DATA FROM A PHASE 3 CLINICAL TRIAL PROGRAMME OF GUSELKUMAB IN A BIO-NAÏVE PATIENT POPULATION

P. Richette - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

guselkumab (IV)

IDENTIFYING BARRIERS IN EARLY RECOGNITION AND MANAGEMENT OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A RETROSPECTIVE REVIEW

A. Nandagudi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

IDENTIFYING THEORY-DRIVEN THERAPEUTIC CONTENT FOR A SMARTPHONE APP FOR THE SELF-MANAGEMENT OF SJOGREN’S SYNDROME

M. Campbell - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Filters

45280 Abstracts